ACOR News and Press, Acorda Therapeutics Inc. From 08/07/22

Acorda Therapeutics, Inc. (ACOR) Q2 2022 Results Conference Call August 04, 2022 04:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - CEO Mike Gesser - CFO Presentation Operator Ladies and gentlemen, w...

Acorda Therapeutics press release ( NASDAQ: ACOR ): Q2 Non-GAAP EPS of -$3.15. Revenue of $31.05M (-2.3% Y/Y). For the full year 2022, Acorda continues to expect AMPYRA net revenue to be $68 – $78 million, and operating expenses to be $110 – $120 million....

INBRIJA ® (levodopa inhalation powder) Q2 2022 U.S. net revenue of $7.4 million; 16% increase from Q2 2021; 100% increase over Q1 2022 Ex-U.S. INBRIJA Q2 additional revenue of $1.9 million AMPYRA ® (dalfampridine) Q2 2022 net revenue of $18.2 million; maintai...

Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a webcast/conference call in conjunction with its second quarter 2022 update and financial results on Thursday, August 4 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://eve...

3 Tips For Investing in Biotech Penny Stocks in 2022 If you’re considering investing in biotech penny stocks right now, there is a lot to know. In general, we have seen a major amount of volatility in the stock market in the past few months. And with rising interest rates and cli...

What Is A Recession? What happens during a recession? A recession is two consecutive quarters of negative GDP growth. It could also be considered a contracting economy with slowing consumption, less production, and higher unemployment. Thanks to the latest string of Consumer Price Index...

3 Top Penny Stocks to Add to Your Watchlist Right Now On Thursday, penny stocks and blue chips saw another bearish day of trading. This comes as the S&P 500 dropped by over 3.6% with the NASDAQ down by over 4.5% at midday. The main reason for this comes as the Fed recently announced...

Neurology-focused nano-cap biotech Acorda Therapeutics (NASDAQ:ACOR) climbed over 50% on Thursday in reaction to the German launch of its inhalational Parkinson’s disease drug Inbrija in collaboration with Esteve Pharmaceuticals. Inbrija is indicated in Europe for intermitten...

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA ® 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the EU for the intermittent treatment of episodic motor fluctuations (OFF episo...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...